Cargando…
Disease Differentiation and Monitoring of Anti-TNF Treatment in Rheumatoid Arthritis and Spondyloarthropathies
Rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA) are comprehensive immunological disorders. The treatment of these disorders is limited to ameliorating the symptoms and improving the quality of life of patients. In this study, serum samples from RA, AS, and PsA p...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307996/ https://www.ncbi.nlm.nih.gov/pubmed/34299006 http://dx.doi.org/10.3390/ijms22147389 |
_version_ | 1783728176229253120 |
---|---|
author | Bogunia-Kubik, Katarzyna Wojtowicz, Wojciech Swierkot, Jerzy Mielko, Karolina Anna Qasem, Badr Wielińska, Joanna Sokolik, Renata Pruss, Łukasz Młynarz, Piotr |
author_facet | Bogunia-Kubik, Katarzyna Wojtowicz, Wojciech Swierkot, Jerzy Mielko, Karolina Anna Qasem, Badr Wielińska, Joanna Sokolik, Renata Pruss, Łukasz Młynarz, Piotr |
author_sort | Bogunia-Kubik, Katarzyna |
collection | PubMed |
description | Rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA) are comprehensive immunological disorders. The treatment of these disorders is limited to ameliorating the symptoms and improving the quality of life of patients. In this study, serum samples from RA, AS, and PsA patients were analyzed with metabolomic tools employing the 1H NMR method in combination with univariate and multivariate analyses. The results obtained in this study showed that the changes in metabolites were the highest for AS > RA > PsA. The study demonstrated that the time until remission or until low disease activity is achieved is shortest (approximately three months) for AS, longer for RA and longest for PsA. The statistically common metabolite that was found to be negatively correlated with the healing processes of these disorders is ethanol, which may indicate the involvement of the gut microflora and/or the breakdown of malondialdehyde as a cell membrane lipid peroxide product. |
format | Online Article Text |
id | pubmed-8307996 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83079962021-07-25 Disease Differentiation and Monitoring of Anti-TNF Treatment in Rheumatoid Arthritis and Spondyloarthropathies Bogunia-Kubik, Katarzyna Wojtowicz, Wojciech Swierkot, Jerzy Mielko, Karolina Anna Qasem, Badr Wielińska, Joanna Sokolik, Renata Pruss, Łukasz Młynarz, Piotr Int J Mol Sci Article Rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA) are comprehensive immunological disorders. The treatment of these disorders is limited to ameliorating the symptoms and improving the quality of life of patients. In this study, serum samples from RA, AS, and PsA patients were analyzed with metabolomic tools employing the 1H NMR method in combination with univariate and multivariate analyses. The results obtained in this study showed that the changes in metabolites were the highest for AS > RA > PsA. The study demonstrated that the time until remission or until low disease activity is achieved is shortest (approximately three months) for AS, longer for RA and longest for PsA. The statistically common metabolite that was found to be negatively correlated with the healing processes of these disorders is ethanol, which may indicate the involvement of the gut microflora and/or the breakdown of malondialdehyde as a cell membrane lipid peroxide product. MDPI 2021-07-09 /pmc/articles/PMC8307996/ /pubmed/34299006 http://dx.doi.org/10.3390/ijms22147389 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bogunia-Kubik, Katarzyna Wojtowicz, Wojciech Swierkot, Jerzy Mielko, Karolina Anna Qasem, Badr Wielińska, Joanna Sokolik, Renata Pruss, Łukasz Młynarz, Piotr Disease Differentiation and Monitoring of Anti-TNF Treatment in Rheumatoid Arthritis and Spondyloarthropathies |
title | Disease Differentiation and Monitoring of Anti-TNF Treatment in Rheumatoid Arthritis and Spondyloarthropathies |
title_full | Disease Differentiation and Monitoring of Anti-TNF Treatment in Rheumatoid Arthritis and Spondyloarthropathies |
title_fullStr | Disease Differentiation and Monitoring of Anti-TNF Treatment in Rheumatoid Arthritis and Spondyloarthropathies |
title_full_unstemmed | Disease Differentiation and Monitoring of Anti-TNF Treatment in Rheumatoid Arthritis and Spondyloarthropathies |
title_short | Disease Differentiation and Monitoring of Anti-TNF Treatment in Rheumatoid Arthritis and Spondyloarthropathies |
title_sort | disease differentiation and monitoring of anti-tnf treatment in rheumatoid arthritis and spondyloarthropathies |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307996/ https://www.ncbi.nlm.nih.gov/pubmed/34299006 http://dx.doi.org/10.3390/ijms22147389 |
work_keys_str_mv | AT boguniakubikkatarzyna diseasedifferentiationandmonitoringofantitnftreatmentinrheumatoidarthritisandspondyloarthropathies AT wojtowiczwojciech diseasedifferentiationandmonitoringofantitnftreatmentinrheumatoidarthritisandspondyloarthropathies AT swierkotjerzy diseasedifferentiationandmonitoringofantitnftreatmentinrheumatoidarthritisandspondyloarthropathies AT mielkokarolinaanna diseasedifferentiationandmonitoringofantitnftreatmentinrheumatoidarthritisandspondyloarthropathies AT qasembadr diseasedifferentiationandmonitoringofantitnftreatmentinrheumatoidarthritisandspondyloarthropathies AT wielinskajoanna diseasedifferentiationandmonitoringofantitnftreatmentinrheumatoidarthritisandspondyloarthropathies AT sokolikrenata diseasedifferentiationandmonitoringofantitnftreatmentinrheumatoidarthritisandspondyloarthropathies AT prussłukasz diseasedifferentiationandmonitoringofantitnftreatmentinrheumatoidarthritisandspondyloarthropathies AT młynarzpiotr diseasedifferentiationandmonitoringofantitnftreatmentinrheumatoidarthritisandspondyloarthropathies |